Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
These details help narrow the product choice and make syringe listings easier to compare
The specification table on this page covers identity, formula, molecular mass, physical form, solubility, storage, and lot-level analytical information
Coverage policies change frequently, so providers should verify current formulary status with their state Medicaid agency
Nerve Cell Rejuvenation B12 repairs and protects myelin nerve sheaths
US$ 21.40
US$ 25.32
US$ 25.61
US$ 20.55
US$ 21.27
US$ 20.48
